Cronos Group Inc
Cronos Group Inc (CRON) is a Canadian cannabis company that develops, cultivates and markets cannabis products for medical and adult-use markets. Investors should know it operates through cultivation facilities, consumer brands and international initiatives while seeking scale and product diversification. Cronos has attracted strategic capital and focuses on innovation in categories such as consumer cannabis products and cannabinoid research. With a market capitalisation of about $1.34B, the company sits among mid‑cap cannabis producers and is sensitive to pricing, regulatory change and capital markets conditions. Key considerations include regulatory risk, competitive pressure from domestic and international producers, and the potential for further financing or dilution as it invests to grow. Performance can be volatile and past performance is not indicative of future results. This summary is for educational purposes only and is not personalised investment advice; investors should assess suitability and consider seeking regulated advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cronos Group's stock, indicating confidence in its future growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CRON
Vice Arbitrage
Get exposure to companies leading the transformation of once-prohibited activities into booming legal industries. These carefully selected stocks represent market leaders capitalizing on shifting regulations in sports betting, cannabis, and more, unlocking tremendous growth potential.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth potential
Product innovation and expanding adult‑use markets could support growth, though outcomes depend on regulation, competition and execution.
Strategic partnerships
Partnerships and investment can help access distribution and capital, but rely on counterparties and favourable market conditions.
Volatile returns
Cannabis stocks are often volatile and sensitive to regulatory shifts and capital needs; investors should expect price swings and possible losses.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
